Trial Profile
Open-label, Single-arm, Phase II, Prospective, Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Erdheim-Chester disease
- Focus Adverse reactions; Therapeutic Use
- 05 Nov 2015 Planned end date changed from 1 Nov 2014 to 1 Dec 2015, as reported by ClinicalTrials.gov.
- 05 Nov 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 14 Jun 2014 Results of an interim analysis of the first 3 patients were presented at the 15th Annual Congress of the European League Against Rheumatism.